DOCSLIB.ORG

Pergolide, Terguride and N,N'-Spacer-Linked Oligomers Of

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pergolide, Terguride and N,N'-Spacer-Linked Oligomers Of Physiol. Res. 53: 35-43, 2004 Pergolide, Terguride and N,N'-spacer-linked Oligomers of Both Interact with 5-HT2A Receptors of Rat Tail Artery V. KŘEN, E. EICH1, H. H. PERTZ1 Institute of Microbiology, Laboratory of Biotransformation, Academy of Sciences of the Czech Republic, Prague, Czech Republic, 1Institut für Pharmazie, Freie Universität Berlin, Germany Received November 5, 2002 Accepted February 27, 2003 Summary Pergolide, terguride and N,N'-spacer-linked oligomers of both have been tested for their ability to interact with 5-hydroxytryptamine(HT)2A receptors of rat tail artery. Pergolide was a potent partial agonist (pEC50 7.5, Emax 55 %) and antagonized 5-HT-induced contractions (pKP 7.2). Pergolide dimer 3 with a p-xylene spacer between the indole nitrogens (N-1) displayed somewhat lower agonist potency than pergolide (pEC50 7.0, Emax 55 %, pKP 6.6). The contractile responses to pergolide and dimer 3 were antagonized by the 5-HT2A receptor antagonist ketanserin (pA2 9.4, 9.1). In contrast to pergolide dimer 3, pergolide dimers 5 and 9 with an alkyl and an aralkyl spacer between the piperidine nitrogens (N-6) lacked agonism and displayed low affinity at 5-HT2A receptors (pA2 < 5.5). Terguride behaved as an insurmountable antagonist of 5-HT (pA2 8.4). Oligomers of terguride showed 5 to 50-fold lower affinity. It is concluded that pergolide and terguride show a high affinity for 5-HT2A receptors, but dimerization (oligomerization) of both drugs fails to increase affinity. Key words Pergolide • Terguride • Oligomers of pergolide and terguride • 5-HT2A receptors • Contraction • Rat tail artery Introduction tryptamine (5-HT) receptors and α-adrenoceptors (for review see Pertz and Eich 1999). Due to their agonist activity at dopamine The aim of the present study was to characterize receptors pergolide (compound 1) and terguride the interaction of pergolide and terguride and their dimers (compound 2) (Fig. 1) are currently available for the with 5-HT2A receptors in the isolated rat tail artery. We treatment of Parkinson's disease (Rinne 1987). While used the so-called bivalent ligand approach that pergolide is a potent agonist of the D1 and D2 class of represents a strategy for medicinal chemists to design dopamine receptors (Fuller and Clemens 1991), terguride potent and selective receptor ligands by combining two or (dihydrolisuride) shows partial agonist activity at the D2 more pharmacophores in a single molecule (Portoghese class of dopamine receptors (Stephens et al. 1990). Just as 1989, 1992, Halazy et al. 1996) (Figs 2 and 3). Previous the well established drug bromocriptine, pergolide and studies on 5-HT1B/1D receptors have demonstrated that terguride are ergoline derivatives of which the spectrum dimerization of 5-HT receptor ligands resulted in higher of adverse effects is similar due to the powerful affinities for this subtype (Perez et al. 1998). We now interaction with nearly all subtypes of 5-hydroxy- report the preparation of oligomers of pergolide and PHYSIOLOGICAL RESEARCH ISSN 0862-8408 2004 Institute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic Fax +420 241 062 164 E-mail: [email protected] http://www.biomed.cas.cz/physiolres 36 Křen et al. Vol. 53 terguride, respectively, in order to find out whether these Methods compounds show activity at vascular 5-HT2A receptors of the rat. Materials Chemicals used for synthesis were reagent-grade mostly from Sigma-Aldrich; solvents were dried and distilled prior to use. Drugs were obtained from the N following sources: cocaine-HCl (Merck, Darmstadt, S O H3C NH Germany), 5-hydroxytryptamine creatinine sulphate (Janssen, Beerse, Belgium), ketanserin tartrate (Janssen), 8 7 H H prazosin-HCl (RBI, Natick, MA, USA). 10 6N CH N 3 H 13 11 5 H 16 Chemistry 4 NMR spectra were measured on a Varian 12 HN HN INOVA-400 spectrometer (399.90 and 100.56 MHz for 1 13 1 (pergolide) 2 (terguride) H and C, respectively) in CDCl3 or d6-DMSO at 30 ºC. Chemical shifts were referenced to the residual solvent Fig. 1. Chemical structures of pergolide and terguride signal (δH 7.265, δC 77.0; δH 2.50, δC 39.6. 2D NMR) experiments (gCOSY, TOCSY, HMQC, HMBC) were run using the default parameters in the available Varian S S software. The pulse sequence for 1D-TOCSY was CH H C 3 3 obtained from the Varian User Library. Positive ion MALDI mass spectra were H H N N measured on a Bruker BIFLEX reflectron time-of-flight H H mass spectrometer (Bruker-Franzen, Bremen, Germany) equipped with a multiprobe sample inlet, a griddles N N delayed extraction ion source and a nitrogen laser S N α O (337 nm). A saturated solution of -cyano-4- H3C 3 NH hydroxycinnamic acid in aqueous 50 % acetonitrile/0.1 % H TFA was used as a MALDI matrix. Spectra were N H + N CH3 calibrated externally using the monoisotopic [M+H] ion H H of α-cyano-4-hydroxycinnamic acid and a peptide N standard (angiotensin II, Aldrich). N 4 Preparation of compounds 3, 4, 5, 6a-e, 7 and 8 S Compounds 3, 4, 5, 6a-e, 7 and 8 were prepared H3C S CH3 as described previously (Křen et al. 2001, 2002). H N H N β H 1,4 -Di[8 ’- (methylthiomethyl) ergoline - 6’- yl - methyl] H benzene (compound 9) HN The title compound was prepared as described NH 5 for compound 5 (Křen et al. 2001) in 67 % yield as a + yellowish amorphous powder. MS MALDI [M + H] S S CH 1 H3C 3 (found 647.5, required 647.32 for C40H47N4S2). H NMR (DMSO) δ: 1.01 (ddd, J = 12.4, 12.2, 12.2, 2H), 1.77 (dd, H H N N J = 11.2, 11.2, 2H), 1.92 (m, 2H), 2.00 (s, 6H), 2.34 (m, H H 4H), 2.44 (dd, J = 13.1, 6.4, 2H), 2.62 (ddd, J = 14.9, 10.9, 1.4, 2H), 2.71 (m, 2H), 2.89 (m, 2H), 3.03 (m, 2H), HN NH 9 3.38 (d, J = 13.8, 2H), 3.51 (dd, J = 14.9, 4.0, 2H), 4.22 (d, J = 13.8, 2H), 6.77 (ddd, J = 7.2, 1.2, 0.6, 2H), 6.99 Fig. 2. Chemical structures of ergot alkaloid dimers (dd, J = 2.1, 1.4, 2H), 7.02 (dd, J = 8.2, 7.2, 2H), 7.12 2004 Pergolide and Terguride Oligomer Interaction with 5-HT2A Receptors 37 (ddd, J = 8.2, 0.8, 0.6, 2H), 7.30 (s, 4H), 10.60 (d, J = d, 110.32 s, 111.97 d, 118.50 d, 122.08 d, 126.09 s, 2.1, 2H). 13C NMR (DMSO) δ: 15.46 q, 27.15 t, 33.96 t, 128.54 d (2 C), 132.92 s, 133.21 s, 137.89 s. 34.63 d, 38.20 t, 40.60 d, 56.54 t, 58.43 t, 65.12 d, 108.69 6a X = -CH - N N 2 O O 6b X = -(CH ) - HN NH 2 6 H H H C N N CH 6c X = H CCH 3 3 2 2 H H CH2 6d X = N N (X) CH2 CH2 6e X = CH2 N O NH N N N O O O HN H N CH3 HN NH H H H H H3C N NCH H3CN 3 H N H H N N N N N N H H H NCH3 H3C N N CH H H H 3 NH HN NH O O O 7 N N N 8 Fig. 3. Chemical structures of terguride dimers and oligomers 1,6-Di[8β‘-(methylthiomethyl)ergoline-1’-yl-]hexane within 3 h as indicated by TLC: silica gel F254 plates (compound 10) (Merck), CHCl3-MeOH-NH3 94.5 : 5.5 : 0.1 (v/v). The Finely powdered KOH (370 mg, 6.6 mmol) was spots were visualised by UV light and charred with 10 % mixed with DMSO (2 ml) and stirred for 10 min. H2SO4 in ethanol where N-1-unsubstituted ergolines gave Depropylpergolide (compound 1a) (135 mg, 0.5 mmol) blue spots and substituted compounds (dimers) gave grey was added and the stirring was continued for further spots. The product had quite similar Rf like compound 1a. 30 min. The mixture turns green indicating deprotonation The reaction mixture was poured into water (40 ml), the of N-1. After cooling to 10 ºC, 1,6-dibromohexane precipitate was filtered off, washed with water till neutral (54 mg, 0.22 mmol, dissolved in 2 ml of DMSO) was pH and dried affording 130 mg of the crude product. slowly added in portions. The reaction was completed Flash chromatography (silica gel, CHCl3-MeOH-NH3 38 Křen et al. Vol. 53 97 : 3 : 0.1 (v/v)) afforded pure compound 10 as the artery to rub off the endothelium. Up to 12 cylindrical amorphous yellow foam (52 mg, 33 %). MS MALDI [M segments (3-4 mm long) were horizontally suspended + + H] (found 627.2, required 627.35 for C38H51N4S2). between two L-shaped stainless steel hooks (diameter 1 H NMR (CDCl3, 30 ºC) δ: 1.28 (ddd, J = 13.3, 12.1, 0.15 mm) and mounted in a 20-ml organ bath filled with 11.9, 2H), 1.33 (m, 4H), 1.79 (m, 4H), 2.08 (m, 2H), 2.16 modified Krebs-Henseleit solution of the following (s, 6H), 2.47 (dd, J = 11.9, 11.7, 2H), 2.48 (dd, J = 13.2, composition (mM): NaCl 118, KCl 4.7, CaCl2 2.5, 7.3, 2H), 2.54 (dd, J = 13.2, 6.6, 2H), 2.77 - 2.90 (m, 8H), MgSO4 1.2, KH2PO4 1.2, NaHCO3 25, and D-glucose 10.
Load more

Recommended publications
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Structure, Function, and Pharmaceutical Ligands of 5-Hydroxytryptamine 2B Receptor
    pharmaceuticals Review Structure, Function, and Pharmaceutical Ligands of 5-Hydroxytryptamine 2B Receptor Qing Wang 1,2 , Yu Zhou 2 , Jianhui Huang 1 and Niu Huang 2,3,* 1 School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China; [email protected] (Q.W.); [email protected] (J.H.) 2 National Institute of Biological Sciences, No. 7 Science Park Road, Zhongguancun Life Science Park, Beijing 102206, China; [email protected] 3 Tsinghua Institute of Multidisciplinary Biomedical Research, Tsinghua University, Beijing 102206, China * Correspondence: [email protected]; Tel.: +86-10-80720645 Abstract: Since the first characterization of the 5-hydroxytryptamine 2B receptor (5-HT2BR) in 1992, significant progress has been made in 5-HT2BR research. Herein, we summarize the biological function, structure, and small-molecule pharmaceutical ligands of the 5-HT2BR. Emerging evidence has suggested that the 5-HT2BR is implicated in the regulation of the cardiovascular system, fibrosis disorders, cancer, the gastrointestinal (GI) tract, and the nervous system. Eight crystal complex structures of the 5-HT2BR bound with different ligands provided great insights into ligand recognition, activation mechanism, and biased signaling. Numerous 5-HT2BR antagonists have been discovered and developed, and several of them have advanced to clinical trials. It is expected that the novel 5-HT2BR antagonists with high potency and selectivity will lead to the development of first-in-class drugs in various therapeutic areas. Keywords: GPCR; 5-HT2BR; biased signaling; agonist; antagonist Citation: Wang, Q.; Zhou, Y.; Huang, J.; Huang, N. Structure, Function, and Pharmaceutical Ligands of 5-Hydroxytryptamine 2B Receptor. 1. Introduction Pharmaceuticals 2021, 14, 76.
    [Show full text]
  • Aripiprazole Attenuates the Discriminative-Stimulus and Subject-Rated Effects of D-Amphetamine in Humans
    Neuropsychopharmacology (2005) 30, 2103–2114 & 2005 Nature Publishing Group All rights reserved 0893-133X/05 $30.00 www.neuropsychopharmacology.org Aripiprazole Attenuates the Discriminative-Stimulus and Subject-Rated Effects of D-Amphetamine in Humans 1 1,2 1,2 3,4,5 1,3,6 Joshua A Lile , William W Stoops , Andrea R Vansickel , Paul EA Glaser , Lon R Hays ,1,2,3 and Craig R Rush* 1 2 Department of Behavioral Science, College of Medicine, University of Kentucky, Lexington, KY, USA; Department of Psychology, College of Arts 3 and Sciences, University of Kentucky, Lexington, KY, USA; Department of Psychiatry, College of Medicine, University of Kentucky, Lexington, KY, 4 5 USA; Department of Anatomy and Neurobiology, College of Medicine, University of Kentucky, Lexington, KY, USA; Department of Pediatrics, College of Medicine, University of Kentucky, Lexington, KY, USA; 6Department of Internal Medicine, College of Medicine, University of Kentucky, Lexington, KY, USA The results of animal research suggest that the use of partial agonists at dopamine (DA) D2 receptors may be an effective strategy for the treatment of stimulant dependence. Aripiprazole is an atypical antipsychotic that has partial agonist activity at D2 receptors. In this experiment, seven human participants with a history of nontherapeutic stimulant use learned to discriminate 15 mg oral D-amphetamine. After acquiring the discrimination (ie X80% correct responding on four consecutive sessions), the effects of a range of doses of D- amphetamine (0, 2.5, 5, 10, and 15 mg), alone and in combination with aripiprazole (0 and 20 mg), were assessed. D-Amphetamine alone functioned as a discriminative stimulus, produced prototypical subject-rated drug effects (eg increased ratings of Active, Alert, Energetic) and elevated cardiovascular indices.
    [Show full text]
  • Treatment of Problem Cocaine Use a Review of the Literature the of Review a Literature
    TREATMENT OF PROBLEM COCAINE USE COCAINE PROBLEM OF TREATMENT A REVIEW OF THE LITERATURE LITERATURE REVIEW ISBN 92-9168-274-8 ISBN EMCDDA literature reviews Treatment of problem cocaine use: a review of the literature EMCDDA literature reviews — Treatment of problem cocaine use Acknowledgements This literature review is based on a consultant report by Christian Haasen and Katja Thane, Institut für Interdisziplinäre Sucht- und Drogenforschung (ISD), Hamburg, at the Zentrum für Interdisziplinäre Suchtforschung (ZIS) of the University of Hamburg (Service Contract CT.06.RES.144.1.0). EMCDDA project managers: Dagmar Hedrich and Alessandro Pirona. Other contributors to this project included Prepress Projects, Rosemary de Sousa and Peter Thomas. Cataloguing data European Monitoring Centre for Drugs and Drug Addiction, 2007 EMCDDA Literature reviews — Treatment of problem cocaine use: a review of the literature Lisbon: European Monitoring Centre for Drugs and Drug Addiction 2007 — 50 pp. — 21 x 29.7 cm Language: EN Catalogue Number: TD-XB-06-001-EN-N ISBN: 92-9168-274-8 ISSN: 1725-0579 © European Monitoring Centre for Drugs and Drug Addiction, 2007. Reproduction is authorised provided the source is acknowledged. Rua da Cruz de Santa Apolónia 23-25, PT-1149-045 Lisbon, Portugal Tel: (+351) 21 811 3000 Fax: (+351) 21 813 1711 [email protected] http://www.emcdda.europa.eu 3 EMCDDA literature reviews — Treatment of problem cocaine use List of abbreviations ADHD attention deficit hyperactivity disorder BBD blood-borne disease CA Cocaine Anonymous
    [Show full text]
  • Tapi-Party-Content-1566784086.Pdf
    Product Name Tapi Tech DMF Status IP File** US EU JP KR Abaloparatide Abemaciclib Abiraterone Acetate Acyclovir Adapalene Afatinib * Alclometasone dipropionate Alendronate sodium * Allopurinol Amcinonide Amitriptyline HCl Amlodipine besylate * Anastrozole Anidulafungin Apixaban Apremilast * Aripiprazole Atenolol Atomoxetine HCl Atorvastatin calcium * Atosiban Acetate Atracurium besylate CEP Azacitidine Azithromycin dihydrate Aztreonam Beclomethasone dipropionate * Betamethasone acetate Betamethasone base Betamethasone dipropionate Betamethasone valerate * TAPI can provide several different polymorphs or processes of this product. To obtain complete DMF files of a specific product's polymorph or process, please contact your account manager. Additional DMFs or Tech Files are available upon request ** Tech File relevant only for products prior to 1st DMF All subject to the disclaimer on the last page Product Name Tapi Tech DMF Status IP File** US EU JP KR Bicalutamide Bimatoprost Bivalirudin Bleomycin sulfate Bortezomib Brexpiprazole Bromocriptine mesylate Budesonide * Buprenorphine base Buprenorphine HCl Butorphanol tartrate Cabazitaxel Cabergoline Calcipotriene * Calcitriol Candesartan Cilexetil CEP Capecitabine Carbidopa Carboplatin Carfilzomib Carvedilol base Carvedilol phosphate Caspofungin acetate Chlormadinone acetate Ciclosporin Cilostazol Cinacalcet HCl Cisatracurium besylate Cisplatin Clarithromycin * TAPI can provide several different polymorphs or processes of this product. To obtain complete DMF files of a specific product's
    [Show full text]
  • Management of Parkinson's Disease: an Evidence-Based Review
    Movement Disorders Vol. 17, Suppl. 4, 2002, p. i 2002 Movement Disorder Society Published by Wiley-Liss, Inc. DOI 10.1002/mds.5554 Editorial Management of Parkinson’s Disease: An Evidence-Based Review* Although Parkinson’s disease is still incurable, a large number tomatic control of Parkinson’s disease; prevention of motor com- of different treatments have become available to improve quality plications; control of motor complications; and control of non- of life and physical and psychological morbidity. Numerous jour- motor features. Based on a systematic review of the data, efficacy nal supplements have appeared in recent years highlighting one conclusions are provided. On the basis of a narrative non-system- or more of these and disparate treatment algorithms have prolifer- atic approach, statements on safety of the interventions are given ated. Although these are often quite useful, this “mentor analy- and finally, a qualitative approach is used to summarize the impli- sis” approach lacks the scientific rigor required by modern evi- cations for clinical practice and future research. dence-based medicine standards. The Movement Disorder Soci- This mammoth task has taken two years to complete and the ety, with generous but unrestricted support from representatives task force members, principal authors and contributors are to be of industry, have, therefore, commissioned a systematic review congratulated for their outstanding work. Physicians, the of the literature dealing with the efficacy and safety of available Parkinson’s disease research community and most of all patients treatments. The accompanying treatise is the result of a scrupu- themselves should welcome and embrace the salient findings of lous evaluation of the literature aimed at identifying those treat- this report as an effort to improve clinical practice.
    [Show full text]
  • Medicament De Medicament De International Nr
    Medicament de Medicament de International Nr. estimat de Nr. de pacienti Data autorizarii Nr. Numar investigatie Aria Denumirea Data aprobarii Data Inceperii Inchidere Cod Protocol investigatie clinica Placebo Solicitant Sponsor / Faza pacienti pt. inrolati in studiului clinic de Inchidere studiu crt. EudraCT clinica terapeutică studiului Comisiei de Etica Studiului Temporara testat national Romania Romania catre ANMDM comparator A Phase III Randomised, Double-Blind, Parallel Group, Quintiles Romania SRL Multicentre Study to Compare the Efficacy, Safety, SB3-G31-BC, version 1.0, dated Bujor Eugen Almasan Pharmacokinetics and Immunogenicity between SB3 1 2013-004172-35 SB3 (trastuzumab biosimilar) Herceptin® (trastuzumab) Nu Afecţiuni oncologice Samsung Bioepis Co., Ltd. internaţional III 45 05.06.2014 28.05.2014 25.06.2014 14.02.2017 08.11.2013 E-mail: bujor- (proposed trastuzumab biosimilar) and Herceptin® in Women [email protected] with Newly Diagnosed HER2 Positive Early or Locally Advanced Breast Cancer in Neoadjuvant Setting PAREXEL International Romania SRL A multicenter, prospective, randomized, open label study to CRLX030A3301, version 00, dated Novartis Pharma Services 2 2013-002513-35 serelaxin (RLX030) standard-of-care Nu Afecţiuni cardiovasculare Mirela Bogdan internaţional assess the effect of serelaxin versus standard of care in III 56 25.06.2014 04.08.2014 25.04.2017 22.03.2017 13.09.2013 Romania SRL E-mail: acute heart failure (AHF) patients [email protected] The Study of the Immunogenity and Reactogenity
    [Show full text]
  • Comprehensive List of Cross-Reactive and Non Cross-Reactive Compounds
    Comprehensive List of Cross-Reactive and Non Cross-Reactive Compounds Rev.A 10-8-2002 TOX Specificity-Chemical Name Biosite Inc. Page 1 Highest Conc. Tested Conc. Giving Positive TRADE NAME CHEMICAL NAME DRUG CLASS (ng/ml) (ng/ml) Sectral Acebutolol Antihypertensive 100,000 Ethanal Acetaldehyde Solvent 10,000,000 Tylenol/Paracetamol/APAP Acetaminophen Analgesic 1,000,000 Acetanilide Acetanilide Analgesic 100,000 Diamox Acetazolamide Diuretic 100,000 Dymelor Acetohexamide Antidiabetic 1,000,000 Acetone Acetone Solvent 10,000,000 Notensil Acetopromazine Tranquilizer 100,000 Mucomyst Acetyl-l-cysteine, N- Mucolytic 100,000 LAAM Acetylmethadol, l-a- Narcotic analgesic 100,000 Aspirin Acetylsalicylic acid Analgesic 1,000,000 Aspirin metabolite Acetylsalicylic acid metab.(Salicylic acid) Aspirin metabolite 1,000,000 Aspirin metabolite Acetylsalicylic acid metab.(Salicyluric acid) Aspirin metabolite 100,000 Acyclovir Acyloguanosine Antiviral 100,000 Dowacide Q Adamantane, (1-(3-Chloroallyl)-3,5,7-triaza-1-azonia)- Antibacterial 100,000 Gumbaral Adenosylmethionine, S- Anti-inflammatory 100,000 Deracyn Adinazolam Benzodiazepine 100,000 BZO 1,000 Deracyn metabolite Adinazolam, Desmethyl Benzodiazepine metabolite 100,000 BZO 250 HSA Albumin, Human Protein 5,000,000 Proventil/Ventolin Albuterol Bronchodilator 200,000 Octalene Aldrin Insecticide 100,000 Fosamax Alendronate Bone reabsorption inhibitor 200,000 Diadol Allobarbital Barbiturate 100,000 BAR 150 Zyloprim Allopurinol Antiurolithic 100,000 Nisentil Alphaprodine Narcotic analgesic 100,000 Xanax
    [Show full text]
  • Process for Preparing a High Drug Load Tablet
    (19) TZZ ¥_T (11) EP 2 285 355 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 9/20 (2006.01) A61J 3/10 (2006.01) 24.01.2018 Bulletin 2018/04 B01J 2/22 (2006.01) B07B 7/00 (2006.01) (21) Application number: 09742166.3 (86) International application number: PCT/EP2009/055628 (22) Date of filing: 08.05.2009 (87) International publication number: WO 2009/135948 (12.11.2009 Gazette 2009/46) (54) PROCESS FOR PREPARING A HIGH DRUG LOAD TABLET VERFAHREN ZUR HERSTELLUNG EINER TABLETTE MIT HOHEM WIRKSTOFFGEHALT PROCÉDÉ POUR PRÉPARER UN COMPRIMÉ À FORTE CHARGE EN SUBSTANCE MÉDICAMENTEUSE (84) Designated Contracting States: • HEILAKKA, Erkki AT BE BG CH CY CZ DE DK EE ES FI FR GB GR FI-00950 Helsikni (FI) HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR (74) Representative: Teuten, Andrew John et al Sagittarius IP (30) Priority: 09.05.2008 FI 20080352 Three Globeside Fieldhouse Lane (43) Date of publication of application: Marlow, Buckinghamshire SL7 1HZ (GB) 23.02.2011 Bulletin 2011/08 (56) References cited: (73) Proprietor: Atacama Labs Oy WO-A1-98/35672 WO-A1-99/11261 00100 Helsinki (FI) WO-A1-99/25343 WO-A1-2006/066930 WO-A1-2009/101258 WO-A2-2008/056021 (72) Inventors: WO-A2-2009/135950 WO-A2-2009/135951 • POLITI, Giovanni US-A1- 2004 126 429 FI-00310 Helsinki (FI) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • Review of Pharmacological Therapies in Fibromyalgia Syndrome Winfried Häuser1,2*, Brian Walitt3, Mary-Ann Fitzcharles4 and Claudia Sommer5
    Häuser et al. Arthritis Research & Therapy 2014, 16:201 http://arthritis-research.com/content/16/1/201 REVIEW Review of pharmacological therapies in fibromyalgia syndrome Winfried Häuser1,2*, Brian Walitt3, Mary-Ann Fitzcharles4 and Claudia Sommer5 Abstract This review addresses the current status of drug therapy for the management of fibromyalgia syndrome (FMS) and is based on interdisciplinary FMS management guidelines, meta-analyses of drug trial data, and observational studies. In the absence of a single gold-standard medication, patients are treated with a variety of drugs from different categories, often with limited evidence. Drug therapy is not mandatory for the management of FMS. Pregabalin, duloxetine, milnacipran, and amitriptyline are the current first-line prescribed agents but have had a mostly modest effect. With only a minority of patients expected to experience substantial benefit, most will discontinue therapy because of either a lack of efficacy or tolerability problems. Many drug treatments have undergone limited study and have had negative results. It is unlikely that these failed pilot trials will undergo future study. However, medications, though imperfect, will continue to be a component of treatment strategy for these patients. Both the potential for medication therapy to relieve symptoms and the potential to cause harm should be carefully considered in their administration. The desire to take medicine is perhaps the greatest feature a cure. Drug prescription has been the foundation of which distinguishes man from animals. medical care over the past several decades, driven by the Sir William Osler (1849–1919) success of many pharmacologic interventions for various medical conditions. This success has positioned drug prescription at the center of the practice of medicine Introduction and has become entrenched in patient expectations for ’ Roughly 2% of the developed worlds population meet ei- medical care [11].
    [Show full text]
  • United States Patent (19) 11 Patent Number: 5,371,000 Hummel-Maquardt Et Al
    USOO537,000A United States Patent (19) 11 Patent Number: 5,371,000 Hummel-Maquardt et al. 45) Date of Patent: Dec. 6, 1994 54 PROCESS FOR THE PRODUCTION OF tive Stimulus Properties...' J. Med. Chem, 1985, vol. ERGOLINE DERVATIVES 28, pp. 1252-1255. 75 Inventors: Heidi Hummel-Maquardt; Mario Primary Examiner-Mukund J. Shah Kennecke; Alfred Weber; Klaus Assistant Examiner-Y. N. Gupta Nickisch; Gregor Haffer, all of Attorney, Agent, or Firm-Millen, White, Zelano & Berlin, Germany Branigan 73) Assignee: Schering Aktiengesellschaft, Berlin, 57 ABSTRACT Germany A process for the production of ergoline derivatives of 21 Appl. No.: 930,692 general formula I is described 22, PCT Filed: Feb. 6, 1992 R3 (I) 86 PCT No.: PCT/DE92/00088 S 371. Date: Oct. 7, 1992 S 102(e) Date: Oct. 7, 1992 87, PCT Pub. No.: WO92/13857 PCT Pub. Date: Aug. 20, 1992 30 Foreign Application Priority Data Feb. 8, 1991 DE Germany ............................. 4104379 in which the bonds 51 int. Cl. ..................... C12P 17/18; C07D 457/14 . represent two single-bonds or a double bond and a 52 U.S.C. .................................... 435/119; 435/121; single bond. 435/886; 546/70 R1 means a hydrogen atom or an alkyl group with 1-6 58) Field of Search .................... 546/70,435/42, 119, carbon atoms 435/121,886 R2 symbolizes a hydrogen atom or an alkyl group with 56) References Cited 1-6 carbon atoms, PUBLICATIONS R3 represents a carboxyl group or a grouping of formula Ishii et al. Journal of Chemical Society, Perkin I, 902-905, 1980. Ishii, H.
    [Show full text]